These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 21744485

  • 1. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST, Rey K, He J, Flanagan J, Fish BJ, Rogers ZR, Wang WC, Ware RE, BABY HUG Investigators.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):170-2. PubMed ID: 21744485
    [Abstract] [Full Text] [Related]

  • 2. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE.
    Blood; 1999 Sep 01; 94(5):1550-4. PubMed ID: 10477679
    [Abstract] [Full Text] [Related]

  • 3. Impact of hydroxyurea on clinical events in the BABY HUG trial.
    Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC, BABY HUG Investigators.
    Blood; 2012 Nov 22; 120(22):4304-10; quiz 4448. PubMed ID: 22915643
    [Abstract] [Full Text] [Related]

  • 4. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.
    Thompson BW, Miller ST, Rogers ZR, Rees RC, Ware RE, Waclawiw MA, Iyer RV, Casella JF, Luchtman-Jones L, Rana S, Thornburg CD, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik S, Howard TH, Luck L, Wang WC.
    Pediatr Blood Cancer; 2010 Feb 22; 54(2):250-5. PubMed ID: 19731330
    [Abstract] [Full Text] [Related]

  • 5. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW, BABY HUG investigators.
    Lancet; 2011 May 14; 377(9778):1663-72. PubMed ID: 21571150
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE, REACH Investigators.
    Lancet Haematol; 2024 Jun 14; 11(6):e425-e435. PubMed ID: 38701812
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 8. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 9. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study.
    Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, Iyer RV, Sarnaik S, Rogers ZR, Wang WC, BABY HUG Investigators.
    Pediatr Blood Cancer; 2012 Oct 25; 59(4):675-8. PubMed ID: 22190441
    [Abstract] [Full Text] [Related]

  • 10. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
    Nnebe-Agumadu U, Adebayo IA, Nnodu O, Adekile A.
    Pediatr Blood Cancer; 2020 Oct 25; 67(10):e28632. PubMed ID: 32743869
    [No Abstract] [Full Text] [Related]

  • 11. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
    Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.
    Blood; 2004 Mar 15; 103(6):2039-45. PubMed ID: 14630791
    [Abstract] [Full Text] [Related]

  • 12. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T, Topazian H, Kamthunzi P, Chen J, Kambalame I, Mafunga P, Mumba N, Chiume-Chiphaliwali M, Paseli K, Key N, Gopal S, Hoffman I, Ataga K, Westmoreland K.
    Blood Adv; 2018 Nov 30; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract] [Full Text] [Related]

  • 13. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
    Sadaf A, Quinn CT, Korpik JB, Pfeiffer A, Reynaud M, Niss O, Malik P, Ware RE, Kalfa TA, McGann PT.
    Blood Cells Mol Dis; 2021 Sep 30; 90():102576. PubMed ID: 34020272
    [No Abstract] [Full Text] [Related]

  • 14. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
    Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, Wang WC.
    Medicine (Baltimore); 2014 Dec 30; 93(28):e215. PubMed ID: 25526439
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 30; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.
    Pediatrics; 2008 Dec 30; 122(6):1332-42. PubMed ID: 19047254
    [Abstract] [Full Text] [Related]

  • 17. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.
    Blood; 2002 Jan 01; 99(1):10-4. PubMed ID: 11756146
    [Abstract] [Full Text] [Related]

  • 18. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M, Mizuno T, Vinks AA.
    Blood Cells Mol Dis; 2017 Sep 01; 67():143-147. PubMed ID: 28807656
    [Abstract] [Full Text] [Related]

  • 19. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU.
    Pediatrics; 2008 Dec 01; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract] [Full Text] [Related]

  • 20. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE.
    J Pediatr; 2001 Dec 01; 139(6):790-6. PubMed ID: 11743503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.